Accelerators of Osteogenesis by Recombinant Human Bone Morphogenetic Protein-2
Bone morphogenetic protein (BMP) appears to be one of the most promising cytokine and for clinical use in reconstructive surgery for bony defects and augmentation. To evaluate the effect of basic fibroblast growth factor (bFGF), FK506, elcatonin, and hyperbaric oxygenation (HBO) on osteoinduction by...
Saved in:
Main Authors: | , , |
---|---|
Format: | Book |
Published: |
AboutScience Srl,
2007-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_c18d6392e364482a9f6cd443204df002 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Yasunori Okubo |e author |
700 | 1 | 0 | |a Kenji Kusumoto |e author |
700 | 1 | 0 | |a Kazuhisa Bessho |e author |
245 | 0 | 0 | |a Accelerators of Osteogenesis by Recombinant Human Bone Morphogenetic Protein-2 |
260 | |b AboutScience Srl, |c 2007-01-01T00:00:00Z. | ||
500 | |a 1177-3928 | ||
520 | |a Bone morphogenetic protein (BMP) appears to be one of the most promising cytokine and for clinical use in reconstructive surgery for bony defects and augmentation. To evaluate the effect of basic fibroblast growth factor (bFGF), FK506, elcatonin, and hyperbaric oxygenation (HBO) on osteoinduction by recombinant human bone morphogenetic protein-2 (rhBMP-2), 2 or 5 μg of rhBMP-2 was implanted into intramuscular sites of rats. At 21 days after implantation, the osteoinductive activity in the treatment group and control group was compared radiographically, biochemically, and histologically. The amount of new bone in the treatment group was signifi cantly greater than that in the control group. The alkaline phosphatase activity and calcium content in the treatment group were signifi cantly higher than those in the control group. These results suggest that bFGF, FK506, elcatonin, and HBO accelerated the activity and rate of osteoinduction by rhBMP2. These results may be useful when BMP is applied clinically in near future. | ||
546 | |a EN | ||
690 | |a FK506 | ||
690 | |a Basic fibroblast growth factor (bFGF) | ||
690 | |a elcatonin | ||
690 | |a hyperbaric oxygenation (HBO) | ||
690 | |a Recombinant human bone morphogenetic protein | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Drug Target Insights, Vol 2, Pp 55-60 (2007) | |
787 | 0 | |n http://la-press.com/article.php?article_id=88 | |
787 | 0 | |n https://doaj.org/toc/1177-3928 | |
856 | 4 | 1 | |u https://doaj.org/article/c18d6392e364482a9f6cd443204df002 |z Connect to this object online. |